Locabiosol
Recall
|
Medicines
|
21/04/2016
The marketing authorization holder has informed its supplied customers in a letter dated 20.04.2016 that the marketing authorizations of medicinal products containing fusafungin (Locabiosol / Bioparox / Locabiotal / Fusaloyos as oral spray, nasal spray or as solution) will be revoked within the EU.These medicines are used for the treatment of upper respiratory tract infections such as rhinopharyngitis.In Austria, this concerns "Locabiosol 1 % - Dosierspray", which is now being recalled prior to the cancellation of the marketing authorization.
| Name of the medicinal product | Locabiosol 1 % -Dosierspray |
|---|---|
| Marketing authorisation number(s) | 1-22703 |
| Marketing authorisation holder | Servier Austria GmbH |
| Batch number(s) | Alle in der Laufzeit befindlichen Chargen |
| Classification of the recall | 3 |
| BASG reference number | INS - 640.001 - 1684 |
Further inquiry note
Page last modified:
12/07/2022